BIOXYNE LIMITED (BXN) - How GMP MDMA And Psilocybin Are Reshaping Access For Treatment‑Resistant Patients

A 149% revenue surge, first‑to‑market GMP MDMA in Australia, and a plan to scale faster than demand—Sam Watson, CEO of Bioxyne, joins us to unpack how a focused manufacturer turns emerging therapeutics into real‑world access. We dig into the mechanics behind record growth, the patient need driving MDMA and psilocybin uptake, and why replicable GMP capacity across Australia, the UK, and Europe is Bioxyne’s not‑so‑secret weapon.

Sam explains how medicinal cannabis remains the commercial engine while psychedelic therapeutics validate a long‑term bet on treatment‑resistant depression and PTSD. With authorised prescriber pathways opening and imports giving way to local GMP supply, clinics gain reliable access and patients get consistent, pharmacy‑grade dosing. We talk through the numbers—upgraded adjusted EBITDA guidance to 16–19 million—and the process upgrades that power it: automation, digitised quality systems, and operating leverage as volumes climb.

We also map the international play. Germany leads as a prescriber‑led, pharmacy‑dispensed market where cannabis flower dominates and Bioxyne targets five to ten tons over the next year through strong local partnerships. The UK mirrors Australia’s earlier stage, making it ripe for a copy‑and‑paste facility to relieve supply bottlenecks. Finally, Sam outlines how rapid clean room buildouts, short payback cycles, and white‑label reliability for 300+ brands create a durable moat: faster turnaround, fewer stockouts, and scalable quality at GMP standards.

If you’re tracking ASX‑listed growth stories, the evolution of medicinal cannabis, or the practical path for MDMA and psilocybin in regulated care, this conversation offers data, strategy, and on‑the‑ground execution. Follow and subscribe, share this with a friend who invests in healthcare, and leave a quick review to help others find the show.

Transcript

Andrew Musgrave

Welcome again to ASX Briefs, where we explore the companies’ making waves on the ASX. And today we're joined by Sam Watson, the CEO of Bioxyne Limited, an Australian pharmaceutical manufacturer and a leader in the production of pharmaceutical grade cannabis pastilles and alternative therapeutics. Sam, thanks for joining me today and welcome to the ASX Briefs podcast.

Sam Watson

Morning Andrew, good to be here.

Andrew Musgrave

Now, Sam, for investors that may be new to the Bioxyne story, can you give us a brief overview of the company and the role your subsidiary, Breathe Life Sciences, plays in the global market?

Sam Watson

Sure. So Bioxyne publicly listed on ASX, Frankfurt, Breathe Life Sciences is the wholly owned subsidiary. The group is focused on pharmaceutical manufacturing of finished products, so finished medicines, so patient-ready medicine products. Areas that we specialize in, and we focus in are indications, so conditions for patients with unmet clinical needs. And our current portfolio includes medicinal cannabis, MDMA, and psilocybin. And we operate in Australia, the UK, Germany, and several other markets. Those are our key markets.

Andrew Musgrave

Okay, and you've just reported a record first half FY26 with revenue up 149% to 31.3 million. So, can you give us an overview of the primary drivers behind this growth?

Sam Watson

So, the primary drivers behind that growth are the Australian, the UK, and the German medicinal cannabis markets. MDMA and psilocybin is a new category for the world, but also for us. We are seeing impressive growth numbers from those new compounds and those medicine products that we're manufacturing, primarily in Australia. The Australian market is growing phenomenally quickly, and we are gaining more and more market share, you know, quarter to quarter. New entry into the European markets and the UK. We've got a long way to go, but the opportunity is massive, and we're doing our best to make the most of it.

Andrew Musgrave

Now, in the first half of FY26, you achieved a major milestone with the commercial release and supply of the first Australian-made GMP certified MDMA capsules. More recently, you announced initial purchase orders for GMP manufactured psilocybin capsules. So, how significant are these early commercial results for validating your strategic investment in psychedelic therapeutics?

Sam Watson

So, it's a super exciting space, Andrew. And psychedelics, you know, present an opportunity and give hope for patients which aren't quite being, well, with patients with conditions that aren't quite being met by existing treatment options. So, it's a space where big pharma haven't quite been able to fill the demand. And in some indications, some conditions, more than 30% of patients don't respond to existing treatment options. So, these investigational drugs that we're manufacturing, and remember we were the first company in Australia to be licensed by the TGA to manufacture MDMA and psilocybin capsules. We're still the only company that can do both. It's a huge potential opportunity over the next 10 years as we see increasing levels of depression, treatment resistance to depression, PTSD. And what we're hoping is that these medicines become more widely available and that we're driving that growth and that access for patients.

Andrew Musgrave

And with approximately 300,000 Australians suffering from treatment-resistant depression, how is the company positioned to scale supply for authorized prescribers via the TGA's pathway over the next 12 months?

Sam Watson

So, before we started manufacturing in Australia, these medicines had to be imported, which is a slow, lengthy process. It's very hard for local clinics and prescribers to have consistent access. What we also are doing is manufacturing under GMP in consistent, you know, high-quality batches that meet pharmaceutical standards, which delivers a much more consistent medicine product for patients that uh that psychiatrists are prescribing these products to. And our vision for this is to become the market leader globally to manufacture these finished product medicines, both for clinical trials and for the authorized prescriber schemes. It's early days still, but we're growing that part of the business rapidly in Australia and hoping to expand overseas in the in the you know in the coming year.

Andrew Musgrave

Okay, now looking at your earnings revenue guidance for FY26 remains at between 65 and 75 million, but you've significantly upgraded your adjusted EBITDA guidance to between 16 and 19 million. So, what internal efficiencies or margin expansion initiatives have allowed you to nearly double your previous earnings expectations?

Sam Watson

Yeah, it's a significant uplift in in our adjusted EBITDA forecast. And it's important to note that this is our second year of profitability. So, we're a young business. You know, 24 months ago, we were doing 8 million a year. We're now, you know, coming close in the next sort of six months to doing eight million a month, we're expecting. So, with that, we are seeing efficiencies and scale, economies of scale in our local Australian manufacturing operations. We are automating systems, we're bringing in digitized systems, digital quality systems, which allows the same number of team members to do, you know, 50% more work. So those sorts of processes. And as we grow, we expect to continue seeing improved profitability. But you know, as only the second year of profitability, there's a bit of fluctuation. It's hard to forecast accurately. So, we have given a range, and that range is 16.5 million on the on the low end to 19 million on the top end.

Andrew Musgrave

Now, at a more macro level, the company has been active internationally from a dual listing on the Frankfurt Stock Exchange to securing non-dilutive funding for a UK GMP facility. So, aside from Australia, which international markets do you see as the most immediate catalysts for the remainder of the year?

Sam Watson

Europe is a big growth opportunity for us, as is the UK. We see them slightly separately because the UK market is more similar to Australia when it comes to particularly medicinal cannabis products. And medicinal cannabis has been the primary driver of our commercial growth over the last couple of years and will be for the next one to two, before we sort of expand into other product categories, potentially new, you know, non-controlled, maybe controlled drugs as well. We see Germany, Poland, possibly France and Spain coming online. Germany is our primary focus in the European market. You know, it's a billion euro a year medicinal cannabis market, prescriber-led, pharmacy dispensed. We have a fantastic partnership and local supply arrangement there. We are making very good traction. You know, the German market's probably 150 tons a year of cannabis flour, and it is primarily, primarily flour that that market consumes. Sort of 95% of prescriptions are for cannabis flour products. And we're pushing to be a big part of that. We're pushing to, you know, five to ten tons over the coming 12 months. In the UK, our plan is and what we are implementing now is a very similar site to what we've built in Australia. And that is because the opportunity in the UK is similar to what we saw in Australia two, three years ago. There's a gap in manufacturing. There is so much patient demand and clinic demand, but very few people keeping up with the growth of the industry manufacturing the products required. So, there's a lot of importing, there's a lot of manual manufacturing. So, bringing our automated systems and our scale into the UK is a huge opportunity as a manufacturer of these medicines.

Andrew Musgrave

Now, finally, Sam, just to wrap things up, as we look ahead, how does the expansion of your GMP clean room and storage capacity late last year support your vision of becoming a market-leading multinational pharmaceutical manufacturer?

Sam Watson

Rolls off a tongue. One of the key strengths of our business is the ability to quickly roll out new production space, new clean rooms, new manufacturing facilities. And in Australia, we've been very fortunate that we have a significant-sized site licensed that we can expand into. Now, currently, we're only using probably less than a third of our entire footprint. So, we can rapidly build new clean rooms, new controlled drug storage in a space of months. Like the four most recent clean rooms we erected came up in three months. The payback time on those clean rooms at full capacity is six to eight weeks. So, for us, it's you know, scaling up rapidly, but also rapidly servicing our clients. So, when a client, because we're a white label manufacturer for over 300 different brands in Australia, and the patients that are buying those brands need they, you know, they need a constant supply. So, for our clients to run our product, it's very bad news. So, we can't let that happen. So having capacity and being able to have quick turnaround times on product manufacturing and delivery is really important, and that's one of the key reasons we've been so successful. We have a faster turnaround time than any other manufacturer in Australia.

Andrew Musgrave

Okay, Sam. Well, it's been great to chat today to get an update on where the company is at. So, thanks for your time, and we look forward to further updates from Bioxyne in the upcoming months.

Sam Watson

Brilliant. Thank you, Andrew.

Andrew Musgrave

That concludes this episode of ASX Briefs. Don't forget to subscribe, and we look forward to catching you on our next episode.